Fixed combination of repaglinide and metformin in the management of type 2 diabetes
Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascu...
Enregistré dans:
Auteur principal: | Robert Moses |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/be193c0f21574bcd8f8d324553d948c1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
par: Robert G Moses
Publié: (2010) -
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
par: Moses R
Publié: (2010) -
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
par: Jonathan K Reynolds
Publié: (2009) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
par: Fleming JW, et autres
Publié: (2015) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
par: Karen Barnard, et autres
Publié: (2010)